Atlas Trials

A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults

Clinical trial NCT05736835 · COMPLETED

Trial details

NCT number
NCT05736835
Sponsor
CyanVac LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2023-09-21
Primary completion
2025-12-16
Enrollment
227

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.